Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Turn Therapeutics Inc. - Common Stock (NQ:TTRX)

9.305 +0.495 (+5.62%)
Streaming Delayed Price Updated: 10:06 AM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,319
Open 8.820
Bid (Size) 9.000 (500)
Ask (Size) 9.610 (100)
Prev. Close 8.810
Today's Range 8.810 - 9.505
52wk Range 2.570 - 26.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
From Turn Therapeutics, Inc.
Via Business Wire

Performance

YTD
+98.4%
+98.4%
1 Month
+84.1%
+84.1%
3 Month
+165.1%
+165.1%
6 Month
+100.1%
+100.1%
1 Year
+32.9%
+32.9%

More News

Read More
News headline image
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Appoints Arthur Golden to Board of Directors
From Turn Therapeutics
Via GlobeNewswire
News headline image
Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings ↗
Via Benzinga
Topics Stocks
News headline image
US Stocks Mixed; Nasdaq Falls Over 50 Points ↗
Via Benzinga
News headline image
Stock Market Today: S&P 500, Nasdaq Futures Tumble As Fed Minutes Signal Tariff-Related Uncertainty—PepsiCo, Delta Air Lines, Levi Strauss In Focus ↗
Via Benzinga
Topics Economy Stocks

Frequently Asked Questions

Is Turn Therapeutics Inc. - Common Stock publicly traded?
Yes, Turn Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Turn Therapeutics Inc. - Common Stock trade on?
Turn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Turn Therapeutics Inc. - Common Stock?
The ticker symbol for Turn Therapeutics Inc. - Common Stock is TTRX on the Nasdaq Stock Market
What is the current price of Turn Therapeutics Inc. - Common Stock?
The current price of Turn Therapeutics Inc. - Common Stock is 9.305
When was Turn Therapeutics Inc. - Common Stock last traded?
The last trade of Turn Therapeutics Inc. - Common Stock was at 07/10/26 10:06 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.